Skip to main content
Addgene
Showing: 1 - 6 of 6 results

  1. pAAV-Ef1a-fDIO-GCaMP6s (AAV8)

    Viral Prep
    #105714-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from pAAV-Ef1a-fDIO-GCaMP6s (#105714). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-GCaMP6s plasmid DNA. EF1a-driven, Flp recombinase-dependent expression of GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals
    Depositor
    Rylan Larsen
    Promoter
    Ef1a, Human elongation factor-1 alpha
    Tags
    None
    Available since
    Oct. 11, 2019
    Availability
    Academic Institutions and Nonprofits only

  2. pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (AAV5)

    Viral Prep
    #105715-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Rylan Larsen
    Promoter
    Ef1a, Human elongation factor-1 alpha
    Tags
    None
    Available since
    Oct. 20, 2020
    Availability
    Academic Institutions and Nonprofits only

  3. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV9)

    Viral Prep
    #26966-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    April 6, 2018
    Availability
    Academic Institutions and Nonprofits only

  4. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV5)

    Viral Prep
    #26966-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    Feb. 14, 2018
    Availability
    Academic Institutions and Nonprofits only

  5. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV1)

    Viral Prep
    #26966-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    Feb. 14, 2018
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV Retrograde)

    Viral Prep
    #26966-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Karl Deisseroth
    Article
    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.
    Promoter
    EF1a
    Tags
    EYFP (Cre-dependent)
    Available since
    March 27, 2024
    Availability
    Academic Institutions and Nonprofits only
Showing: 1 - 6 of 6 results